430 related articles for article (PubMed ID: 22941165)
1. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
[TBL] [Abstract][Full Text] [Related]
2. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
3. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
4. Integrating US-guided FNAB, BRAF
Ma N; Tian HY; Yu ZY; Zhu X; Zhao DW
Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5565-5574. PubMed ID: 37540271
[TBL] [Abstract][Full Text] [Related]
5. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.
Li C; Aragon Han P; Lee KC; Lee LC; Fox AC; Beninato T; Thiess M; Dy BM; Sebo TJ; Thompson GB; Grant CS; Giordano TJ; Gauger PG; Doherty GM; Fahey TJ; Bishop J; Eshleman JR; Umbricht CB; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2013 Sep; 98(9):3702-12. PubMed ID: 23969188
[TBL] [Abstract][Full Text] [Related]
6. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases.
Zhang Q; Wang Z; Meng X; Duh QY; Chen G
Asian J Surg; 2019 Apr; 42(4):571-576. PubMed ID: 30348606
[TBL] [Abstract][Full Text] [Related]
7. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
[TBL] [Abstract][Full Text] [Related]
8. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
9. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
10. Integrating BRAF
Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
[TBL] [Abstract][Full Text] [Related]
11. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
[TBL] [Abstract][Full Text] [Related]
12. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
13. Conventional Ultrasound, Immunohistochemical Factors and BRAF
Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of central lymph node metastasis and BRAF
Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
[TBL] [Abstract][Full Text] [Related]
16. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
19. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size.
So YK; Son YI; Park JY; Baek CH; Jeong HS; Chung MK
Otolaryngol Head Neck Surg; 2011 Sep; 145(3):422-7. PubMed ID: 21750338
[TBL] [Abstract][Full Text] [Related]
20. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?
Nam JK; Jung CK; Song BJ; Lim DJ; Chae BJ; Lee NS; Park WC; Kim JS; Jung SS; Bae JS
Am J Surg; 2012 Apr; 203(4):436-41. PubMed ID: 21803329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
